on's management will discuss the company's third quarter 2007
performance in a conference call with investors beginning at 5:00 p.m. U.S.
EST on Thursday, November 8, 2007. To participate in the conference call,
dial +1-913-981-5543 and refer to conference code number 6083046. Investors
can listen to the call live by logging on to the company's website at
and clicking on "Investor Information" then "Webcast."
The conference call will be archived and available to investors for one
week after the call.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and marketing of innovative
products in four core therapeutic areas: central nervous system, pain,
oncology and addiction. Cephalon has delivered a seven-year compound annual
growth rate (CAGR) through 2006 greater than 75% and 2006 revenue of $1.760
billion. A member of the Fortune 1000, Cephalon currently employs
approximately 3,000 people in the United States and Europe. U.S. sites
include the company's headquarters in Frazer, Pennsylvania, and offices,
laboratories or manufacturing facilities in West Chester, Pennsylvania,
Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's
European headquarters are located in Maisons-Alfort, France.
The company's proprietary products in the United States include:
PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet)
[C-II], TRISENOX(R) (arsenic trioxide), AMRIX, VIVITROL(R) (naltrexone for
extended-release injectable suspension), GABITRIL(R) (tiagabine
hydrochloride), and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II].
The company also markets numerous products internationally. Full
prescribing information on its U.S. products is available at
http://www.cephalon.com or by calling 1-800-896-5855.
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1
|SOURCE Cephalon, Inc.|
Copyright©2007 PR Newswire.
All rights reserved
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2
. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3
. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA4
. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia5
. Cephalon Quarterly Conference Call Invitation6
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7
. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268
. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9
. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10
. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11
. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results